Cited by 511Cancer Immunotherapy and BiomarkersChemotherapy-induced cardiotoxicity and mitigationCardiac tumors and thrombi

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Open access

Heinzerling, Lucie, Ott, Patrick A., Hodi, F. Stephen, Husain, Aliya N., Tajmir-Riahi, Azadeh, Tawbi, Hussein, Pauschinger, Matthias, Gajewski, Thomas F., Lipson, Evan J., Luke, Jason J.·2016·Journal for ImmunoTherapy of Cancer

DOI 10.1186/s40425-016-0152-yPMC PMC4986340

Open this paper in CoChat — free account Open PDF

Abstract

Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition. However, a plethora of immune-mediated adverse events has been reported with these agents. Immune-mediated cardiotoxicity induced by checkpoint inhibitors has been reported in single cases with variable presentation, including myocarditis and pericarditis. Among six clinical cancer centers with substantial experience in the administration of immune-checkpoint blocking antibodies, eight cases of immune-related cardiotoxicity after ipilimumab and/or nivolumab/pembrolizumab were identified. Diagnostic findings, treatment and follow-up are reported. A large variety of cardiotoxic events with manifestations such as heart failure, cardiomyopathy, heart block, myocardial fibrosis and myocarditis was documented. This is the largest case series to date describing cardiotoxicity of immune-checkpoint blocking antibodies. Awareness, monitoring of patients with pre-existing cardiac disorders and prompt evaluation by the treatment team is essential. Treatment including application of steroids is critical for patient safety.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1186/s40425-016-0152-y

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 Histologic presentation of case 1. Endomyocardial biopsy shows interstitial fibrosis with some interstitial lymphocytes. Signs of hypertrophy are detectableCC BY · PubMed Central

Fig. 2 Histologic presentation of case 5. a H&E stain of the endomyocardial biopsy shows patchy lymphohistiocytic infiltrates associated with myocyte damage, diagnostic for lymphocytic myocarditis. b IHC stain for CD3 highlights in brown T cells within the inflammatory infiltrate (c) IHC stain for CD8 highlights in brown T cells within the inflammatory infiltrate (d) IHC stain for CD68 shows many histiocytes/macrophages within the myocardial inflammationCC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citation
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citation
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Self-citation
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Self-citation
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868

Show all 37 references

Research works printed but not linked: 1

Larkin J, D’Angelo S, Sosman JA, Lebbe C, Brady B, Neyns B, et al. Efficacy and safety of nivolumab (NIVO) monotherapy in the treatment of advanced mucosal melanoma. Pigment Cell Melanoma Res. 2016;28:789.

Sorted by citations

Items 401–500 of 510

Interprofessional Management of Toxicities Related to Cancer Precision Medicine
Abueg, K. D. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.08.005 · Cited by 2
Cardiovascular toxicities of therapy for genitourinary malignancies
Narayan, V., Vaughn, D. J., & Ky, B. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.04.029 · Cited by 2
Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer protocol for a systematic review and network meta-analysis
Han, D., Dong, J., Li, H., Ma, T., Yu, W., & Song, L. (2020) · Medicine · doi:10.1097/md.0000000000018701 · Cited by 2
An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma
Pan, C., Tang, H., Wang, W., Wu, D., Luo, H., Xu, L., & Lin, X.-J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1077477 · Cited by 2
Cardiovascular profile of contemporary treatments of renal cell carcinoma: A single-center prospective study
Lee, K., Lindenfeld, L., Echevarria, M., Hsu, J., Wong, F. L., Narayan, H. K., Lau, C., Cai, L., Pal, S. K., Armenian, S. H., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.03.040 · Cited by 2
The cardiac-related adverse events of PD-1/PD-L1 immunotherapy in advanced or metastatic lung cancer: a RCT-based meta-analysis
Chen, B., Xu, A., He, Y., Zhang, Y., Cheng, D., Fang, Y., Ruan, J., Dai, M., Wang, Y., & Zhang, J. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08344-2 · Cited by 2
Incidence and Immunopathology of Myositis in Rectal Cancer Patients Treated With Neoadjuvant Immune Checkpoint Inhibitors and Chemoradiotherapy: Findings From the CHINOREC Trial
Zirnbauer, R., Hametner, S., Bergler-Klein, J. K., Kuehrer, I., Kulu, A., Ammon, D., Kabiljo, J., Stift, A., Schmid, R. W., Müllauer, L., et al. (2025) · MedComm · doi:10.1002/mco2.70275 · Cited by 2
Cardiovascular effects of innovative therapies in lung cancer
Toffart, A., Pluchart, H., & Girard, N. (2020) · European Respiratory Society eBooks · doi:10.1183/2312508x.10028019 · Cited by 2
Myocarditis Induced by Immunotherapy in Metastatic Melanoma—Review of Literature and Current Guidelines
Czarnecka, A. M., Kleibert, M., Płachta, I., Rogala, P., Wągrodzki, M., Leszek, P., & Rutkowski, P. L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175182 · Cited by 2
Potential of Oncocardiology
Cautela, J., Lalevée, N., & Thuny, F. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.0119 · Cited by 2
Cardiovascular Effects of Cancer Therapy
Minasian, L. M., Davis, M., & Ky, B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00042-6 · Cited by 2
The Complex Picture of New Therapeutic Modalities and Their Potential Cardiovascular Effects, “Cardio-Oncology Challenge Extends to Other Field of Medicine”.
(2017) · doi:10.29199/cdcs.101013 · Cited by 2
Multiple cardiotoxicities during osimertinib therapy
Kobat, H., Davidson, M., Elkonaissi, I., Foreman, E., & Nabhani‐Gebara, S. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231164301 · Cited by 2
Toxicities in Immune Checkpoint Inhibitors
Lee, S. S., Loecher, M., & Puzanov, I. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54948-6.00011-1 · Cited by 2
Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma
Pavlick, A. C., & Weber, J. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_60 · Cited by 3
Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology
Kobat, H., Elkonaissi, I., Dorak, M. T., & Nabhani‐Gebara, S. (2021) · Oncology Reviews · doi:10.4081/oncol.2021.510 · Cited by 2
Commentary: Small Molecule Inhibition of PD-1 Transcription is an Effective Alternative to Antibody Blockade in Cancer Therapy
Taylor, A., & Rudd, C. E. (2019) · Journal of Immunological Sciences · doi:10.29245/2578-3009/2019/1.1167 · Cited by 2
Immune therapy, a double-edged sword for oncolytic viruses
McCormack, R., & Kaur, B. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1650911 · Cited by 2
Blind Spot
Ley, K. F., & Roy, P. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.08.008 · Cited by 2
The Mechanism and Management of Adverse Cardiac Reactions Induced by Immune Checkpoint Inhibitors Therapy
Rong, F., Ji, K., Weng, Y., & Peng, Y. (2020) · Cardiology Research and Practice · doi:10.1155/2020/8367651 · Cited by 1
Myocarditis associated with immune checkpoint inhibitor therapies: diagnostic and treatment strategies
Баллюзек, М. Ф., Проценко, С., & Потиевская, В. (2023) · Voprosy Onkologii · doi:10.37469/0507-3758-2023-69-2-219-226 · Cited by 1
Health Equity in Cardio-oncology: Investigating Mechanistic Causes Behind Adverse Cardiovascular and Cancer Health
Otieno, B., Greenlee, A. N., Ariwodo, S., Carter, P., Ghazi, S. M., Smith, S. A., Addison, D., Quiroga, D. M., & Branch, M. E. (2024) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-024-01037-3 · Cited by 1
New-Onset Arrhythmias in Advanced Lung Cancer Patients Undergoing Anlotinib Treatment
Shang, C., Wang, H., Chen, J., Cao, S., Sun, Y., Sheng, Z., Chu, T., & Zhao, L. (2025) · Cardiovascular Toxicology · doi:10.1007/s12012-025-10070-y · Cited by 1
Targeting ligand PDL1 for cardiotoxicity assessment and cardiac protection in immune-related myocarditis
Li, Y., Li, X., Liu, F., Zhang, H., Guo, J., Liu, G., Wang, J., Zhong, Q., Liu, Q., Liu, L., et al. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2595118 · Cited by 1
Nicotinamide prevents anti-PD1 immune checkpoint inhibitor-associated early stages of cardiotoxicity
Bai, L., Zhao, J., Dong, K., Zhao, M., Zhao, Y., Cong, Q., Wang, Y., Niu, X., Tang, J., & Bai, M. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3116-0 · Cited by 1
Combined Nivolumab and Ipilimumab Therapy Promotes Immune‐Mediated Cardiomyocyte Apoptosis Through TLR4–Myd88–NF‐ Κ b–Driven Activation of the NLRP3 Inflammasome
Gao, M., Liu, X., Wu, L., Jiang, Y., Yu, J., & Zhang, Y. (2026) · Human Mutation · doi:10.1155/humu/8506248 · Cited by 1
Pembrolizumab-Associated Polyserositis with Eosinophilic Pleural Effusion During Adjuvant Therapy for Clear Cell Renal Cell Carcinoma: A Case Report and Targeted Review
Portu, M., Sanz-Beltran, J., Borges, M. A. D., Navarro, J., Arias, A., Alvarez, P., Fernández-Rebollo, A., Reyes, C., Flores, J., Anguera, G., et al. (2026) · Current Oncology · doi:10.3390/curroncol33060314 · Cited by 1
Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy
Naser, A., Morgan, A. A., & Zhang, L. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13080385 · Cited by 1
Oncologic Benefits and Cardiovascular Risks of Pembrolizumab
Park, C. S., Park, Y., Park, J. H., Kwak, S., Rhee, T., Lee, H., Kim, H.-K., Kim, Y.-J., Han, K., & Park, J. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.07.019 · Cited by 1
Inhibition of Programmed Cell Death-1 in Cytotoxic CD8 + T Cells Exacerbates Pressure Overload–Induced Cardiac Injury
Wu, M., Sun, Y., Zhang, Y., Yang, Y.-C., He, Z.-X., Zhou, S., Wang, X., Xiao, H., Yu, M., Miao, C., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.074024 · Cited by 1
Thoracic Imaging of Solid Tumor Patients Treated with Immune Checkpoint Inhibitors
Hammer, M. M. (2018) · Current Radiology Reports · doi:10.1007/s40134-018-0269-5 · Cited by 1
Immune-Related Adverse Toxicities and Clinical Management
Kirchberger, M. C., & Heinzerling, L. (2018) · Springer eBooks · doi:10.1007/978-3-319-78310-9_36 · Cited by 1
Self-citation
Notfälle unter medikamentöser Tumortherapie
Alig, A. H. S., von Bergwelt, M., & Gießen-Jung, C. (2019) · Der Onkologe · doi:10.1007/s00761-019-00672-x · Cited by 1
Cardio-Oncology and Heart Failure
Mitchell, J. D., Sawyer, D. B., & Lenihan, D. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-60987-6.00046-6 · Cited by 1
A Case of ST-Elevation due to a Primitive Extracardiac Origin in a Cancer Patient: Differential Diagnosis and Review of Literature
Valotta, A., Grazioli, G., Leo, L. A., Averaimo, M., & Moccetti, M. (2020) · International Journal of Clinical Cardiology · doi:10.23937/2378-2951/1410205 · Cited by 1
Longitudinal Evaluation of Immune Checkpoint Inhibitor‐Induced Fatigue Syndrome by Rest, Stress, and Speckle‐Tracking Strain Echocardiography
Tsai, K. K., Chang, A. Y., Abouzeid, C. M., Aras, M. A., Fang, Q., Bibby, D., Haghighat, L., Hilton, J. F., DAUD, A. I., & Schiller, N. B. (2025) · Echocardiography · doi:10.1111/echo.70158 · Cited by 1
Cancer Immunotherapy
Arabpour, J., Davodabadi, F., & Nigam, M. (2025) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-96-4959-4_3 · Cited by 1
Potential of Oncocardiology—Reply
Chang, H., & Yeh, E. T. H. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.0122 · Cited by 1
Krebserkrankungen heilen und das Herz schützen
Hohmann, C., Baldus, S. E., & Pfister, R. (2019) · Herz · doi:10.1007/s00059-019-4787-6 · Cited by 1
Current Challenges and Applications of Oncolytic Viruses in Overcoming the Development of Resistance to Therapies in Cancer
Swanner, J. L., Meisen, W. H., McCormack, R., Lewis, C. T., Hong, B., & Kaur, B. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-21477-7_3 · Cited by 1
Eosinophillic Myocarditis Secondary to Metastatic Melanoma
Bryde, R. E., Ray, J. C., Sacco, K. A., Shapiro, B. P., & Cooper, L. T. (2019) · Radiology Cardiothoracic Imaging · doi:10.1148/rcyt.2019190076 · Cited by 1
Machine learning strategies for identifying repurposed drugs for cancer therapy
Lim, H., & Xie, L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819668-7.00003-8 · Cited by 1
Four cases of erysipelas‐like inflammation in patients with metastatic melanoma treated with checkpoint inhibitors
Pföhler, C., Hassel, J. C., Heinzerling, L., & Müller, F. M. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14304 · Cited by 1
Self-citation
Progress in Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Cardiotoxicity
Wang, F., & Qin, S. (2020) · Journal of Cancer Immunology · doi:10.33696/cancerimmunol.2.022 · Cited by 1
Myocarditis and Pericarditis
Jain, A., Bruno, K. A., Matsumori, A., Cooper, L. T., Yamani, M., & Fairweather, D. (2022) · Comprehensive Pharmacology · doi:10.1016/b978-0-12-820472-6.00091-8 · Cited by 1
A Case of Immune Checkpoint Inhibitor-Induced Probable Myocarditis and Treatment Response
Hassan, M. A., Batta, Y., & Afzal, M. A. (2023) · Cureus · doi:10.7759/cureus.39692 · Cited by 1
Research Progress on Cardiotoxicity Associated with Immune Checkpoint Inhibitors
赵, 紫. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13102348 · Cited by 1
Response to letter entitled: ‘Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors’
Heinzerling, L., Rosée, P. G. L., Gutzmer, R., Kramer, R., Keller‐Stanislawski, B., Zierold, S., & Mentzer, D. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.05.028 · Cited by 1
Self-citation
A model informed approach to assess the risk of checkpoint inhibitors induced myocarditisPreprint
van der Vegt, S. A., Wang, Y., Polonchuk, L., Wang, K., Waters, S. L., & Baker, R. E. (2021) · doi:10.31222/osf.io/9paxh · Cited by 1
Bone Marrow–Liver–Thymus ( BLT ) Humanized Mice as a Tool to Assess Checkpoint Inhibitor Adverse Events
Semple, K. M., Knapton, A. D., & Howard, K. E. (2022) · doi:10.1002/9781119535331.ch8 · Cited by 1
Management and Supportive Care of Patients Undergoing Immunotherapy
Rapoport, B. L., & Eeden, R. I. V. (2017) · InTech eBooks · doi:10.5772/67372
Side Effects of Systemic Therapy and Their Clinical Management
Rapisuwon, S., & Gibney, G. T. (2017) · Springer eBooks · doi:10.1007/978-1-4614-7322-0_22-1
Risk of myocarditis in patients with cancer treated with immune checkpoint inhibitors
Kelling, M., Dimza, M., & Dalia, S. M. (2018) · Chronicles of Oncology · doi:10.33582/2638-4248/1004
Managing Checkpoint Inhibitor Symptoms and Toxicity
Pavlick, A. C., & Weber, J. S. (2019) · Springer eBooks · doi:10.1007/978-3-319-46029-1_60-1
Antineoplastic Therapies related Cardiotoxicity
Fu, L., & Bian, Z. (2019) · Madridge Journal of Internal and Emergency Medicine · doi:10.18689/mjiem-1000131
Neue onkologische Therapien und ihre kardiovaskulären Risiken
Totzeck, M., & Rassaf, T. (2020) · Herz · doi:10.1007/s00059-020-04902-6
Cardiovascular Side Effects of Medications for Skin Diseases
Sălăvăstru, C., Suru, A., Popescu, M., & Ţiplica, G. (2021) · Springer eBooks · doi:10.1007/978-3-030-54779-0_22
Neue onkologische Therapien und ihre kardiovaskulären Risiken: Was sollte der Kardiologe kennen?
Totzeck, M., & Rassaf, T. (2020) · Herz
Nebenwirkungsmanagement unter Checkpoint-Inhibitor-Therapie
Schmale, I. (2021) · Onkologische Welt · doi:10.1055/a-1400-8688
Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
Li, R., Zou, X., Shu, H., & Shang, Y. (2021) · Intensive Care Research · doi:10.2991/icres.k.210524.001
Malignant pericardial effusion complicated by cardiac tamponade under atezolizumab
Lardinois, B., Jean-Charles, G., Laurence, M., Randazzo, A., Laurent, T., & Debois, R. (2021) · SAGE Open Medical Case Reports · doi:10.1177/2050313x211036005
Fulminant Myocarditis Complicated with Immune Checkpoint Inhibitor in Patients with Thymoma: Report of Three Cases and Literature ReviewPreprint
Huang, D., Song, F., Zhang, W., Ma, H., Lin, X., Qin, T., & Wang, S. (2021) · Research Square · doi:10.21203/rs.3.rs-707559/v1
Repercussão cardiovascular das terapias anticâncer / Cardiovascular outcomes of anticancer therapies
Silva, J. O., Júnior, M. D. A. L., FERREIRA, I. M. O., & Silva, B. V. N. (2021) · Brazilian Journal of Health Review · doi:10.34119/bjhrv4n5-118
Gestion des toxicités de l’immunothérapie
Ricordel, C., Guen, Y. L., & Léna, H. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00118-x
Analysis of Corticosteroids in Immune Checkpoint Inhibitors (ICI) Induced Myocarditis- A Systematic Review of 352 Screened Articles
Sheikh, M., Patel, S., Nagpal, S., Yukselen, Z., Zahid, S., Jha, V., Sánchez-Velazco, D. F., Marzban, S., & Frontela, O. (2021) · Journal of Surgery and Research · doi:10.26502/jsr.10020186
Conservation Treatment Job # 6630
Horne, A. R. (1875)
Renal and urinary bladder cancer
Xie, Z., & Costello, B. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-68135-3.00047-7
Arrhythmia and device assessment during cancer treatments
Fradley, M. G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-68135-3.00028-3
Gynecologic malignancies
Shea, M., Bouberhan, S., & Cannistra, S. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-68135-3.00045-3
04 / A CHALLENGING CASE OF NEW-ONSET PAROXYSMAL ATRIAL FIBRILLATION WITH RAPID VENTRICULAR RESPONSE SECONDARY TO AUTOIMMUNE THYROIDITIS AFTER A SINGLE DOSE OF NIVOLUMAB-IPILIMUMAB
Brito-Dellan, N. (2018) · doi:10.26226/morressier.5afadd89f314ac000849ad74
Side Effects of Systemic Therapy and Their Clinical Management
Rapisuwon, S., & Gibney, G. T. (2019) · Springer eBooks · doi:10.1007/978-1-4614-7147-9_22
Recomendaciones para el manejo de la cardiotoxicidad relacionada con el tratamiento del cáncer. Parte 2
(2021) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.36.3.7
Systemic Organ Manifestations of Drug Allergy
Lerch, M., & Harr, T. (2022) · Springer eBooks · doi:10.1007/978-3-030-82743-4_4
Diagnostic Methods of Cardiac Immunotherapy Damaging
Manno, G., Lisi, D. D., & Novo, G. (2022) · Current clinical pathology · doi:10.1007/978-3-030-97744-3_6
Management of Patients with Cardiac Toxicity: The Point of View of the Cardiologist
Carbone, A., Inno, A., Islas, F., & Maurea, N. (2022) · Current clinical pathology · doi:10.1007/978-3-030-97744-3_8
Ipilimumab/nivolumab/pembrolizumab
(2017) · Reactions Weekly · doi:10.1007/s40278-017-26215-6
Proarrhythmic effects of cancer therapies
Stępień, J., Bissinger, A., Stępień, B., Przybyłek, Z., Piotrowski, J., & Piotrowski, G. (2022) · In a good rythm · doi:10.5604/01.3001.0016.0698
Etiology and Pathogenesis of Fulminant Myocarditis
Chen, C., & Wang, D. W. (2022) · Springer eBooks · doi:10.1007/978-981-19-5759-8_4
Toxicidad por inmunoterapia en cáncer: una visión oncológica para el internista
Ahmad-Kanan, A. T., Ordóñez, C., Bermudez, S. D. R., & Corredor-Rengifo, D. (2023) · Interdisciplinary Journal of Epidemiology and Public Health · doi:10.18041/2665-427x/ijeph.2.9900
Regulation and diagnosis of cardiovascular diseases by microRNAs derived from immune cells
Domínguez, R. B. (2022) · doi:10.4321/repisalud.16324
Notfälle in der Medikamentösen Tumortherapie
Handke, A. E., Hilser, T., Bögemann, M., Schlack, K., & Grünwald, V. (2023) · Aktuelle Urologie · doi:10.1055/a-2128-4849
Pediatric Cardio-Oncology
Raskin, A., & Ryan, T. D. (2023) · Springer eBooks · doi:10.1007/978-3-030-42937-9_79-1
Pathogenesis, Diagnosis and Treatment of Immune-Related Cardiotoxicity
任, 静. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.143698
Drug-induced immunotoxicity
Mhatre, M., Shinde, S., Kaur, S., Vasdev, N., Tekade, M., Pawar, B. M., Sayyed, A. A., & Tekade, R. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15842-1.00028-4
Manejo en cuidado crítico de la toxicidad severa relacionada con la inmunoterapia en cáncer
Estrada, V. H. N., Franco, D. M., del Valle, A. M., & Vich, C. G.-E. (2023) · Medicina · doi:10.56050/01205498.2307
Use of Infliximab in the Treatment of Immune Checkpoint Inhibitors-Related Myocarditis: A Systematic Review of Case Reports
PHING, K. C., Gnanasan, S., & Tangiisuran, B. (2024) · Malaysian Journal of Pharmaceutical Sciences · doi:10.21315/mjps2024.22.1.7
Side Effects of Melanoma Therapy
Ortiz‐Urda, S., Ho, W. W.-S., & Lee, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-59128-0_7
Diagnosing Immune Checkpoint Inhibitor-Induced Myocarditis: Insights, Challenges, and Uncertainties
Lu, L., Wang, X., & Xu, H. (2024) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2024.0039
Pediatric Cardio-oncology
Raskin, A., & Ryan, T. D. (2024) · Springer eBooks · doi:10.1007/978-3-031-07563-6_79
Notfälle in der Medikamentösen Tumortherapie
Handke, A. E., Hilser, T., Bögemann, M., Schlack, K., & Grünwald, V. (2024) · Onkologische Welt · doi:10.1055/a-2329-1673
Notfälle in der Medikamentösen Tumortherapie
Handke, A. E., Hilser, T., Bögemann, M., Schlack, K., & Grünwald, V. (2024) · TumorDiagnostik & Therapie · doi:10.1055/a-2367-2130
Cardiovascular safety profile of CTLA-4: a pharmacovigilance analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)Preprint
Li, X., Ling, W., Li, X., Wei, R., Chen, S., Tang, J., Zang, J., & Fang, X. (2025) · Research Square · doi:10.21203/rs.3.rs-6307761/v1
Additional file 1 of Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis
Zhou, J., Lee, S., Lakhani, I., Yang, L., Liu, T., Zhang, Y., Xia, Y., Wong, W. T., Bao, K. K. H., Wong, I. C. K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19381075
Additional file 1 of Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems
Ma, R., Wang, Q., Meng, D., Li, K., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.13545671
Additional file 1 of Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets
Luo, X.-Y., Wu, K.-M., & He, X.-X. (2021) · Figshare · doi:10.6084/m9.figshare.14615275
Additional file 1 of Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer
Lecocq, Q., Debie, P., Puttemans, J., Awad, R. M., Beck, L. D., Ertveldt, T., Vlaeminck, Y. D., Goyvaerts, C., Raes, G., Keyaerts, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16921640
Pembrolizumab-associated eosinophilic polyserositis with pericardial involvement during adjuvant therapy for clear cell renal cell carcinoma: a case report and narrative reviewPreprint
Portu, M., Sanz-Beltran, J., Duarte, M. A., Navarro, J., Arias, A., Alvarez, P., Fernández-Rebollo, A., Reyes, C., Flores, J., Anguera, G., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8910623/v1
From unidirectional toxicity to bidirectional systemic interplay in Cardio-Oncology
Wang, J., Wang, R., Yu, L., Li, X., Fang, W., & Wu, Y. (2026) · The Innovation Oncology · doi:10.59717/j.xinn-oncol.2026.100004
Umbrella Systematic Review of the Efficacy and Safety of PD-1 Inhibitors Combined with CTLA-4 Inhibitors in the Treatment of Melanoma
Zhou, Z., Zhu, C., Yang, Q., Ji, C., Ma, L., & Wang, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093869
Immunotherapy: blockade of CTLA-4/B7 and PD-1/PD-L1 pathways in anticancer therapy. Part 2. Clinical aspects
Shukshin, A. A., Rubinstein, A., Головкин, А. С., Моисеева, О. М., & Kudryavtsev, I. V. (2026) · Medical academic journal · doi:10.17816/maj641690

Authors: Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., Pauschinger, M., Gajewski, T. F., Lipson, E. J., & Luke, J. J.
Affiliations: Universitätsklinikum Erlangen (DE)
Dana-Farber Cancer Institute (US)
University of Chicago (US)
The University of Texas MD Anderson Cancer Center (US)
Paracelsus Medizinische Privatuniversität (DE)
Sidney Kimmel Comprehensive Cancer Center (US)
Corresponding author: Heinzerling, Lucie
ORCID: Heinzerling, Lucie
Ott, Patrick A.
Hodi, F. Stephen
Husain, Aliya N.
Tawbi, Hussein
Pauschinger, Matthias
Gajewski, Thomas F.
Lipson, Evan J.
Luke, Jason J.
Venue: Journal for ImmunoTherapy of Cancer
Publisher: BMJ
Published: 2016-08-16
Volume: 4
Issue: 1
Pages: 50-50
ISSN: 2051-1426 (ISSN-L)
DOI: 10.1186/s40425-016-0152-y
PMC: PMC4986340
OpenAlex: W2478478625
Cited by: 511
References: 37
Citations by year: 2026: 21 · 2025: 29 · 2024: 34 · 2023: 43 · 2022: 50 · 2021: 77 · 2020: 78 · 2019: 64 · 2018: 61 · 2017: 50 · 2016: 2
FWCI: 31.82
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
Locations: Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) (submittedVersion, cc-by)
Funders: Melanoma Research Alliance
Celldex Therapeutics
National Institutes of Health
Genentech
National Cancer Institute (K12CA139160)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
Keywords: immune-related cardiotoxicity, CTLA-4 blockade, anti-PD-1 therapy, immune checkpoint inhibitors, ipilimumab, nivolumab, pembrolizumab, myocarditis, pericarditis, heart failure, cardiomyopathy, myocardial fibrosis, atrioventricular block, corticosteroid therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks